Research Progress of TMB in Predicting Prognosis and Efficacy of Lung Cancer

Immune checkpoint inhibitors (ICIs) have changed therapeutic paradigms for patients across multiple cancer types and play Immune checkpoint inhibitors (ICIs) have changed therapeutic paradigms for patients across multiple cancer types and play an important role. However, due to the complexity and individual differences in immunotherapy, not all patients benefit from immunotherapy. an important role. However, due to the complexity and individual differences in immunotherapy, not all patients benefit from immunotherapy. New insights into the role of tumor mutational burden (TMB) suggest that their composition, as well as their functionality, might serve as a New insights into the role of tumor mutational burden (TMB) suggest that their composition, as well as their functionality, might serve as a biomarker to enable optimal patient selection for current systemic therapies and upcoming treatment options. In this paper, we will review TMB biomarker to enable optimal patient selection for current systemic therapies and upcoming treatment options. In this paper, we will review TMB as a biomarker for immunotherapy, assess the efficacy of immunotherapy, present several combinations of biomarkers to improve treatment as a biomarker for immunotherapy, assess the efficacy of immunotherapy, present several combinations of biomarkers to improve treatment prediction, and further evaluate the limitations of TMB as a biomarker of immunotherapy for lung cancer. prediction, and further evaluate the limitations of TMB as a biomarker of immunotherapy for lung cancer.